• Sitemap
• Japanese

On April 4, 2022, Medwatcher Japan submitted a "Fourth Opinion on Avigan - Request To Stop Stockpiling Avigan And Revoke Its Approval" to the Minister of Health, Labor and Welfare.

On March 11, 2022, FUJIFILM Toyama Chemical Co., Ltd. announced that at the end of March this year, it would terminate the enrollment of subjects in the ongoing domestic Phase III clinical trial of Avigan Tablets 200 mg (generic name: favipiravir) in patients with COVID-19. Avigan's trial will now end without showing any efficacy against COVID-19.

We issued our opinion three times, calling for the immediate suspension of Avigan’s use, etc. However, in light of the recent completion of the clinical trial, we request that the MHLW revoke Avigan’s approval, stop its use and stockpiling, summarize the situation surrounding the drug, and explain it to the public.

The full text is in the attached document below.

Our three previously published opinions are also available below.

Table Of Contents

• Privacy Policy

Our members have other regular jobs and volunteer their services free of charge. Our secretariat also serves as part-time basis, and we are currently in the process of facilitating the secretariat function. Therefore, please note that due to limited resources, we might not be able to respond to each inquiry on specific medicine. Thank you for your understanding.